Dose‐ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti‐cancer chemotherapy

Katherine M.W. Pisters, Mark G. Kris, Leslie B. Tyson, Rebecca A. Clark, Richard J. Gralla

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Background. Tropisetron (ICS 205–930) antagonizes the serotonin type 3 receptor and has antiemetic activity in animals given cisplatin. Its mean serum half‐life is 11.1 hours. Methods. In this dose‐ranging trial, 22 patients undergoing anti‐cancer chemotherapy received 24 courses of a single intravenous infusion of tropisetron beginning 30 minutes before chemotherapy. Four dose levels were explored (range, 12–48 mg/m2). Results. Toxicities were mild and included headache, transient elevations of serum alanine transaminase and/or aspartate transaminase levels, and sedation. No akathisia or acute dystonic reactions were observed. Thirty‐six percent of patients had no emesis, and 58% had two or fewer emetic episodes. Ten patients received high‐dose cisplatin (dose, ⩾ 100 mg/m2) as initial chemotherapy. Of these, 30% had no emesis, and 60% had two or fewer episodes. Conclusions. Tropisetron can be administered safely in the doses tested with no dose‐limiting toxicities. The encouraging antiemetic efficacy, mild toxicities, lack of extrapyramidal effects, and convenience of a single 15‐minute infusion regimen make this drug appropriate for study in additional trials. Cancer 1993; 71:226‐30.

Original languageEnglish (US)
Pages (from-to)226-230
Number of pages5
JournalCancer
Volume71
Issue number1
DOIs
StatePublished - Jan 1 1993

Keywords

  • ICS 205–930
  • antiemetic
  • emesis
  • nausea and vomiting
  • serotonin antagonist
  • tropisetron

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dose‐ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti‐cancer chemotherapy'. Together they form a unique fingerprint.

Cite this